Match tier
Confirmed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-09-26
E
Eva R. Palmer
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Role not yet determined Is this you? Add your title
2 pubs
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Eva R. Palmer, a graduate student at the University of Central Arkansas, focuses on leishmaniasis studies, the synthesis of bioactive compounds, and antitumor agents. Her research explores the intersection of biological activity and chemical synthesis. Palmer's recent work includes contributions to the study of bioactive compounds, with a publication in 2024.
Metrics
- Publications: 2
Selected Publications
-
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer (2026)
-
Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs (2024)
Collaboration Network
Top Collaborators
Hayden Roys
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Assyl Arykbayeva
University of Central Arkansas
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Sarah K. Friedman
University of Central Arkansas
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Gabriel Gifford
University of Central Arkansas
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Alex Rogers
University of Central Arkansas (US)
1 shared publication
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Emily N. H. Tran
University of Central Arkansas
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Lucy G. Fry
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Alexx Weaver
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Anne Kidd Bowlin
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Meghan D. Jones
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Michael R. Eledge
University of Arkansas for Medical Sciences (US)
1 shared publication
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Karl W. Boehme
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Gregory R. Naumiec
University of Central Arkansas
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Tiffany Weinkopff
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Maha Hanafi
Cairo University
1 shared publication
In database
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer